Brookline Capital Markets Comments on ADIL Q2 Earnings

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) – Equities research analysts at Brookline Capital Markets issued their Q2 2026 earnings per share estimates for Adial Pharmaceuticals in a research report issued on Monday, May 11th. Brookline Capital Markets analyst K. Dolliver anticipates that the company will earn ($1.40) per share for the quarter. The consensus estimate for Adial Pharmaceuticals’ current full-year earnings is ($7.34) per share. Brookline Capital Markets also issued estimates for Adial Pharmaceuticals’ Q3 2026 earnings at ($1.41) EPS and Q4 2026 earnings at ($1.42) EPS.

Adial Pharmaceuticals (NASDAQ:ADIL) last released its earnings results on Friday, May 8th. The company reported ($1.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.73) by $1.25.

Several other equities research analysts have also issued reports on ADIL. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research note on Monday, April 20th. UBS Group set a $8.00 price objective on Adial Pharmaceuticals in a research note on Wednesday, February 11th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $22.75.

Adial Pharmaceuticals Trading Up 0.7%

Shares of NASDAQ ADIL opened at $1.44 on Tuesday. The stock has a market capitalization of $2.06 million, a price-to-earnings ratio of -0.10 and a beta of 1.27. Adial Pharmaceuticals has a 12-month low of $1.38 and a 12-month high of $18.90. The firm’s 50-day moving average price is $1.74 and its 200-day moving average price is $4.65.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ADIL. Jane Street Group LLC increased its holdings in shares of Adial Pharmaceuticals by 887.3% in the 4th quarter. Jane Street Group LLC now owns 121,841 shares of the company’s stock valued at $27,000 after acquiring an additional 109,500 shares during the period. Citadel Advisors LLC purchased a new position in shares of Adial Pharmaceuticals in the 3rd quarter valued at $51,000. Finally, Armistice Capital LLC purchased a new position in shares of Adial Pharmaceuticals in the 4th quarter valued at $562,000. 16.41% of the stock is currently owned by hedge funds and other institutional investors.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.